Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-35.56%
0%
-35.56%
6 Months
-36.96%
0%
-36.96%
1 Year
-57.35%
0%
-57.35%
2 Years
-82.42%
0%
-82.42%
3 Years
-86.82%
0%
-86.82%
4 Years
-95.28%
0%
-95.28%
5 Years
-94.63%
0%
-94.63%
Physiomics Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.40%
EBIT Growth (5y)
-9.12%
EBIT to Interest (avg)
-0.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
0.66
Tax Ratio
4.84%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.30
EV to EBIT
-0.84
EV to EBITDA
-0.84
EV to Capital Employed
0.84
EV to Sales
0.84
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-50.79%
ROE (Latest)
-41.53%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Jun'23
Jun'23
Jun'22
Change(%)
Net Sales
0.60
0.80
-25.00%
Operating Profit (PBDIT) excl Other Income
-0.60
-0.40
-50.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.50
-0.30
-66.67%
Operating Profit Margin (Excl OI)
-973.70%
-516.70%
-45.70%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2023 is -25.00% vs 14.29% in Jun 2022
Consolidated Net Profit
YoY Growth in year ended Jun 2023 is -66.67% vs -50.00% in Jun 2022
About Physiomics Plc 
Physiomics Plc
Miscellaneous
Physiomics Plc is engaged in the provision of outsourced systems and computational biology services to pharmaceutical companies. The Company is focused on the development of Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials; Cardiac tox prediction service, to predict unwanted toxic side effects of drug candidates in the drug discovery process, and Drug combinations database, for researchers and clinicians to access literature data on pre-clinical and clinical regimens and their effects. Its services include Target Validation, Mechanism of Action Studies, Lead Selection, Clinical Pharmacokinetic/Pharmacodynamics (PK/PD), EASYAP/Cardiac Toxicity Service, Virtual Tumour Preclinical and Virtual Tumour Clinical. It offers a services and technology for predicting cardiac toxicity. It also focuses on offering offer Model Based Drug Development (MBDD) services, which include Population PKPD analysis of clinical data and Back-translational analysis.
Company Coordinates 
Company Details
Magdalen Centre, 1 Robert Robinson Avenue OXFORD None : OX4 4GA
Registrar Details






